CAR-T therapy moves beyond cancer, and autoimmune disease becomes the next proving ground
Dr. Dereck Mush, MD, MBA
What they do
Novocure manufactures the Optune system, which delivers Tumor Treating Fields to disrupt cancer cell division. The wearable therapy is prescribed by oncologists to treat patients diagnosed with glioblastoma and malignant pleural mesothelioma.
The record
- Vertical
- Medical Devices
- Sub-segment
- Cancer therapy systems
- Product type
- Device
- Stage
- Public
- Headquarters
- Root, Switzerland
- Region
- Europe
- Founded
- 2000
- Total funding
- $100M raised
Notable investors: Johnson & Johnson Development Corporation, Pfizer, Index Ventures.
Also in Medical Devices
Related on The Signal
Dr. Dereck Mush, MD, MBA
The Two-Marker CAR-T Test: LNK001's First Patients and the Safety Hypothesis
Dr. Dereck Mush, MD, MBA
A CDMO partnership shows how gene therapy manufacturing is scaling for chronic disease
Dr. Dereck Mush, MD, MBA
The MCED Inflection Point: What Galleri's FDA Panel Backing Means for Cancer Screening
Dr. Dereck Mush, MD, MBA